TABLE 1

Demographics and baseline characteristics of patients receiving fluticasone propionate 500 μg twice daily (FP) or placebo twice daily according to blood eosinophil level

Eosinophils <2%Eosinophils ≥2%
FPPlaceboFPPlacebo
Age years63.8±6.94#64.1±6.8363.5±7.34+63.2±7.74§
Male190 (72)#171 (71)88 (82)+102 (81)§
BMI kg·m−224.91±4.92#25.17±4.5423.61±4.28+24.50±4.84§
White260 (99)#241 (>99)106 (>99)+126 (100)§
Current smoker133 (51)#118 (49)42 (39)+60 (48)§
Smoking pack-years43.2±29.78ƒ43.6±35.58##47.2±30.11¶¶42.7±28.65++
Pre-bronchodilator FEV1 L1.32±0.472§§1.25±0.462ƒƒ1.24±0.444###1.31±0.496¶¶¶
Pre-bronchodilator FEV1 % pred47.3±15.31§§45.5±14.90ƒƒ42.5±14.09###45.4±15.46¶¶¶
Post-bronchodilator FEV1 L1.45±0.485§§1.37±0.470ƒƒ1.36±0.440###1.44±0.496¶¶¶
Post-bronchodilator FEV1 % pred51.8±15.25§§49.9±14.79ƒƒ46.5±13.79###49.9±15.24¶¶¶
Reversibility to salbutamol %4.5±3.5§§4.4±3.35ƒƒ4.1±3.46###4.5±3.52¶¶¶
  • Data are presented as mean±sd or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted. Numbers of patients in each analysis group differed depending on data availability. #: n=263; : n=242; +: n=107; §: n=126; ƒ: n=251; ##: n=214; ¶¶: n=104; ++: n=119; §§: n=261; ƒƒ: n=240; ###: n=106; ¶¶¶: n=124.